文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Hallmarks of cancer resistance.

作者信息

Tufail Muhammad, Hu Jia-Ju, Liang Jie, He Cai-Yun, Wan Wen-Dong, Huang Yu-Qi, Jiang Can-Hua, Wu Hong, Li Ning

机构信息

Department of Oral and Maxillofacial Surgery, Center of Stomatology, Xiangya Hospital, Central South University, Changsha, China.

Institute of Oral Precancerous Lesions, Central South University, Changsha, China.

出版信息

iScience. 2024 May 15;27(6):109979. doi: 10.1016/j.isci.2024.109979. eCollection 2024 Jun 21.

DOI:10.1016/j.isci.2024.109979
PMID:38832007
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11145355/
Abstract

This review explores the hallmarks of cancer resistance, including drug efflux mediated by ATP-binding cassette (ABC) transporters, metabolic reprogramming characterized by the Warburg effect, and the dynamic interplay between cancer cells and mitochondria. The role of cancer stem cells (CSCs) in treatment resistance and the regulatory influence of non-coding RNAs, such as long non-coding RNAs (lncRNAs), microRNAs (miRNAs), and circular RNAs (circRNAs), are studied. The chapter emphasizes future directions, encompassing advancements in immunotherapy, strategies to counter adaptive resistance, integration of artificial intelligence for predictive modeling, and the identification of biomarkers for personalized treatment. The comprehensive exploration of these hallmarks provides a foundation for innovative therapeutic approaches, aiming to navigate the complex landscape of cancer resistance and enhance patient outcomes.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eb2d/11145355/b43ee6e7ecd3/gr7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eb2d/11145355/9e7c6a456012/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eb2d/11145355/d68644f86b01/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eb2d/11145355/8de90acf05e4/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eb2d/11145355/b11c4611d83e/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eb2d/11145355/520b749c291e/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eb2d/11145355/c32aad61bff4/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eb2d/11145355/296364c80187/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eb2d/11145355/b43ee6e7ecd3/gr7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eb2d/11145355/9e7c6a456012/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eb2d/11145355/d68644f86b01/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eb2d/11145355/8de90acf05e4/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eb2d/11145355/b11c4611d83e/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eb2d/11145355/520b749c291e/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eb2d/11145355/c32aad61bff4/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eb2d/11145355/296364c80187/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eb2d/11145355/b43ee6e7ecd3/gr7.jpg

相似文献

[1]
Hallmarks of cancer resistance.

iScience. 2024-5-15

[2]
The role of non-coding RNAs in ABC transporters regulation and their clinical implications of multidrug resistance in cancer.

Expert Opin Drug Metab Toxicol. 2021-3

[3]
Utilizing non-coding RNA-mediated regulation of ATP binding cassette (ABC) transporters to overcome multidrug resistance to cancer chemotherapy.

Drug Resist Updat. 2024-3

[4]
The role of long non-coding RNAs and circular RNAs in cervical cancer: modulating miRNA function.

Front Cell Dev Biol. 2024-2-16

[5]
Novel Implications of MicroRNAs, Long Non-coding RNAs and Circular RNAs in Drug Resistance of Esophageal Cancer.

Front Cell Dev Biol. 2021-11-22

[6]
Non-Coding RNAs in Gastric Cancer: From Malignant Hallmarks to Clinical Applications.

Front Cell Dev Biol. 2021-11-3

[7]
Decoding the regulatory landscape of lncRNAs as potential diagnostic and prognostic biomarkers for gastric and colorectal cancers.

Clin Exp Med. 2024-1-31

[8]
Identification of Novel Long Non-coding and Circular RNAs in Human Papillomavirus-Mediated Cervical Cancer.

Front Microbiol. 2017-9-19

[9]
circRNAs in drug resistance of breast cancer.

Oncol Res. 2022

[10]
Targeting the Warburg effect: A revisited perspective from molecular mechanisms to traditional and innovative therapeutic strategies in cancer.

Acta Pharm Sin B. 2024-3

引用本文的文献

[1]
Cancer Immunotherapy-An Overview.

Cancer Treat Res. 2025

[2]
Unlocking the potential of tumor-targeting peptides in precision oncology.

Oncol Res. 2025-6-26

[3]
Protective effect of purple sweet potatoes ( L.) against rat breast cancer.

Vet World. 2025-5

[4]
Functional Analysis of the PI3K/AKT/mTOR Pathway Inhibitor, Gedatolisib, Plus Fulvestrant with and Without Palbociclib in Breast Cancer Models.

Int J Mol Sci. 2025-6-18

[5]
Exosomal biomarkers and immune checkpoint inhibitors: advancements and future prospects.

Cancer Cell Int. 2025-6-24

[6]
Discovery of novel purine analogues against breast cancer selectively targeting CDK2: optimization, synthesis, biological evaluation and docking study.

Mol Divers. 2025-5-29

[7]
Exploring the Impact of Phenanthroline-Based Glycoconjugated Ru(II) Polypyridyl Photosensitizers on Metastasis-Related Processes.

Chemistry. 2025-7-22

[8]
Insights Into Heart-Tumor Interactions in Heart Failure.

Circ Res. 2025-5-23

[9]
Death-ision: the link between cellular resilience and cancer resistance to treatments.

Mol Cancer. 2025-5-15

[10]
ATM and p53 in aging and cancer: a double-edged sword in genomic integrity.

Biogerontology. 2025-5-5

本文引用的文献

[1]
JAK/STAT in leukemia: a clinical update.

Mol Cancer. 2024-1-26

[2]
Predictive, preventive, and personalized medicine in breast cancer: targeting the PI3K pathway.

J Transl Med. 2024-1-3

[3]
Current Status and Molecular Mechanisms of Resistance to Immunotherapy in Oral Malignant Melanoma.

Int J Mol Sci. 2023-12-8

[4]
Exploiting innate immunity for cancer immunotherapy.

Mol Cancer. 2023-11-27

[5]
Wnt Signaling and Therapeutic Resistance in Castration-Resistant Prostate Cancer.

Curr Pharmacol Rep. 2023-10

[6]
Efficacy and safety of venetoclax in patients with relapsed/refractory multiple myeloma: a meta-analysis.

BMC Cancer. 2023-11-3

[7]
Dietary approaches for controlling cancer by limiting the Warburg effect: a review.

Nutr Rev. 2024-9-1

[8]
Immune check points in cancer treatment: current challenges and perspectives.

Br J Cancer. 2023-10

[9]
Hormetic and synergistic effects of cancer treatments revealed by modelling combinations of radio - or chemotherapy with immunotherapy.

BMC Cancer. 2023-10-27

[10]
Regulation and signaling pathways in cancer stem cells: implications for targeted therapy for cancer.

Mol Cancer. 2023-10-18

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索